Alamar Puts a Real Bid Under the Life-Sciences IPO Window

FREMONT, Calif., April 19, 2026 - Alamar Biosciences gave the life-sciences IPO market a cleaner test than most new issues: a commercial tools company, not a single-asset drug developer, pricing above its initial deal size and then drawing a real opening bid.

The precision proteomics company sold 11.25 million shares at $17 each, the top of its marketed $15 to $17 range, for about $191.3 million in gross proceeds. The share count was lifted from the 9.375 million shares in the earlier prospectus, and the underwriters have a 30-day option for another 1.6875 million shares. Alamar began trading Friday on the Nasdaq Global Select Market under ALMR, opened at $22.60 and was valued at roughly $1.53 billion in its debut, according to Reuters.

That is the market story. The company story is why the deal worked.

Alamar sells instruments, consumables and services built around its NULISA technology and ARGO HT System, a platform designed to detect low-abundance protein biomarkers in blood and other biofluids. It commercially launched ARGO HT in January 2024 and entered the IPO with more than 300 customers across 25 countries, a cumulative installed base above 100 instruments and average annual pull-through above $400,000 per instrument for 2025. The filing says all ten of the top ten biopharma companies by 2024 revenue are customers.

That gives Alamar a different texture from the usual biotech new issue. Investors are not being asked only to price a clinical binary. They are underwriting a young tools-and-diagnostics platform with early commercial adoption, research-use-only products today, and a plan to submit its ARGO HT/DX instrument for FDA marketing authorization in 2027.

The financial profile is still early, but it is not empty. Revenue rose 195% to $74.2 million in 2025 from $25.1 million in 2024, helped by instrument adoption and consumables pull-through. The company also narrowed its loss before income tax to $29.2 million from $47.1 million. At year-end, it had $30.0 million of cash and cash equivalents, $71.0 million of working capital and $64.0 million of total liabilities before the IPO proceeds.

Demand signals were visible before the first print. Bloomberg reported that orders exceeded available shares by more than 10 times, while Fortune cited CEO Yuling Luo saying demand was 11 times the book. That kind of cover matters in a market that has been selective with life-sciences issuers and especially cautious around tools companies since the 2021 boom faded.

The underwriting group also helped frame the book. J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners and Stifel are joint book-running managers. That is a deep healthcare-capital-markets syndicate, and the final terms suggest the group had room to increase the float without cutting price.

Alamar's outside scientific and nonprofit relationships are part of the pitch, but they should be read carefully. The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator made a $10 million investment to support development of Alamar's ARGO HT/DX platform. The Michael J. Fox Foundation is collaborating with Alamar on Parkinson's biomarker assays. The Global Neurodegeneration Proteomics Consortium plans to characterize roughly 40,000 plasma samples using Alamar panels, with support in part from Gates Ventures and the Alzheimer's Disease Data Initiative. These relationships do not guarantee regulatory adoption or diagnostic reimbursement. They do show that the platform has found credible demand in large neurodegeneration research programs.

Use of proceeds is broad: Alamar says the roughly $171.5 million of estimated net proceeds, or $198.2 million if the option is exercised in full, will be used for general corporate purposes. The offering is expected to close Monday, April 20, subject to customary conditions.

The open question is what public investors are really paying for after the first-day pop. At the IPO price, Alamar was already a scarcity asset: a revenue-generating proteomics platform with a fast-growing installed base, blue-chip biopharma customers and a clean top-of-range book. At $22.60, the market added another layer of credit for category demand and IPO-window momentum.

That makes ALMR useful beyond its own ticker. If it holds the bid, it gives bankers another data point that public investors will fund differentiated life-sciences tools companies when commercial traction is visible. If it fades, the read-through is narrower: the market will still pay for growth, but not for every diagnostics story with an elegant platform and a long regulatory road.